All articles by Srivani Venna

Srivani Venna

PTC’s trial of sepiapterin for phenylketonuria achieves primary endpoint

Part 1 of the trial was a run-in phase, where all subjects who were screened received sepiapterin for two weeks.

First subjects in IBC’s Phase Ib trial receive IBC-Ab002

Patients with early Alzheimer’s disease will be randomised into a 3:1 ratio to receive IBC-Ab002 or placebo.

Arrowhead concludes enrolment for familial chylomicronemia syndrome trial

The primary portion of the trial is expected to be completed in the second quarter of next year.

First patient dosed in Inhibikase’s Phase II Parkinson’s disease trial

The primary endpoint of the study is to evaluate the safety, tolerability, and steady-state pharmacokinetics of IkT-148009.

Lynk’s RA therapy trial shows differences in efficacy against placebo

The subjects were randomised into LNK01001 high-dose, low-dose, and placebo groups at a ratio of 1:1:1.

NewAmsterdam Pharma concludes subject enrolment in HeFH trial

The study participants were randomised to receive a placebo or 10mg obicetrapib dosed as a once-daily oral treatment.

Recruitment underway for Cambridge University’s coronavirus vaccine trials

DIOS-CoVax has already been part of trials that were conducted at the NIHR Southampton Clinical Research Facility.

IVERIC bio’s drug meets primary endpoint in geographic atrophy trials

The trials’ post-hoc analysis combined data showed a relationship between GA growth and worsening vision loss.

AbbVie reports positive results from trial of atogepant for migraine

The ELEVATE trial demonstrated reduction in MMDs for episodic migraine patients taking atogepant against a placebo.

Evecxia Therapeutics reports positive data from Phase I trial of EVX-101

All adverse events reported were mild or moderate, generally transient, and consistent with the serotonergic pharmacology.